Labor practices & human rights
At the end of 2017, the total number of employees was 6,245, compared with 6,441 in 2016. The employee absence rate was 2.1% in 2017, compared with 2.0% in 2016.
Novozymes promotes equal opportunities and strengthens diversity in the global workplace. At the end of 2017, 26% of senior management (directors and higher) were women.
Occupational health & safety
Our continuous focus on building awareness and keeping employees safe and healthy has resulted in a lower frequency of occupational accidents: 1.6 per million working hours in 2017, compared with 2.2 in 2016.
Innovation
Novozymes is committed to delivering bioinnovation and launched eight new products in 2017. In 2017, Novozymes had 1,049 active patent families, which comprise the number of inventions that have active patent applications or active patents. See more details about our new products in Novozymes in a nutshell.
Customer engagement
Novozymes conducts an annual customer satisfaction survey and tracks progress on its Net Promoter Score (NPS), which is assessed on a scale from -100 to +100. In 2017, we received an NPS score of +39, compared with +45 in 2016. Despite this decline in score, which can be attributed to changing customer perceptions of account management, the survey results are largely positive.
Community engagement
In 2017, Novozymes engaged more than 188,000 learnersA learner is a person who has been engaged in a Novozymes Educate activity, for example a workshop or an educational activity that requires active participation from the learner., compared with approximately 106,000 in 2016. The increase was due to expansion of our 2016 projects across regions.
- Peder Holk Nielsen
President & CEO
Business ethics
In 2017, Novozymes reinforced its commitment to its business integrity principles. 99% of Novozymes’ employees completed business integrity training in 2017, on par with 2016.
There were no breaches of competition law in 2017. The number of investigated fraud cases increased to 49 in 2017, compared with 44 in 2016. None of the investigated fraud cases had a material financial impact on Novozymes.
